Does LAROTRECTINIB Cause Malignant neoplasm progression? 23 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Malignant neoplasm progression have been filed in association with LAROTRECTINIB (VITRAKVI). This represents 2.9% of all adverse event reports for LAROTRECTINIB.
23
Reports of Malignant neoplasm progression with LAROTRECTINIB
2.9%
of all LAROTRECTINIB reports
6
Deaths
1
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LAROTRECTINIB?
Of the 23 reports, 6 (26.1%) resulted in death, 1 (4.3%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LAROTRECTINIB. However, 23 reports have been filed with the FAERS database.
What Other Side Effects Does LAROTRECTINIB Cause?
Fatigue (56)
Drug ineffective (52)
Dizziness (50)
Death (48)
Pain (42)
Neuropathy peripheral (39)
Nausea (32)
Off label use (31)
Disease progression (27)
Myalgia (23)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LAROTRECTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
LAROTRECTINIB vs LASILIX
LAROTRECTINIB vs LASIX
LAROTRECTINIB vs LASMIDITAN
LAROTRECTINIB vs LATANOPROST
LAROTRECTINIB vs LATANOPROSTENE BUNOD